Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Who Are Not Achieving Glycemic Targets

Part of paid clinical trials in Birmingham, Alabama.

Sponsor
Biomea Fusion Inc.
Study ID
NCT07502495
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • icovamenib 100mg — DRUG
    icovamenib 100mg
  • Placebo — DRUG
    Matching placebo

Study Details

This is a Phase 2, randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of icovamenib in participants with Type 2 Diabetes who are not achieving glycemic targets despite antihyperglycemic medications.

Key Dates

First listed
Mar 31, 2026
Start date
Mar 27, 2026
Status verified
Aug 2026
Primary completion
Mar 31, 2027
Completion
Sep 30, 2027

Study Design

Enrollment
60 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Arm A: icovamenib 100 mg
    icovamenib 100 mg QD in addition to their currently prescribed antihyperglycemic medication(s) for 12 weeks. At Week 12, participants will continue on their currently prescribed antihyperglycemic medication(s). The total duration of the trial is approximately 56 weeks
  • Placebo Comparator: Arm B: placebo matching 100 mg
    placebo matching 100mg QD in addition to their currently prescribed antihyperglycemic medication(s) for 12 weeks. At Week 12, participants will continue on their currently prescribed antihyperglycemic medication(s). The total duration of the trial is approximately 56 weeks

Primary Outcome Measure

To demonstrate that icovamenib 100 mg once daily for 12 weeks is superior to placebo for glycemic control [ Time Frame: 26 weeks ]

Central Contacts

Locations (18)

FacilityCityStateZIPSite coordinators
Central Research Associates, LLC dba Flourish ResearchBirminghamAlabama35205-
Hope Clinical ResearchCanoga ParkCalifornia91303-
Ark Clinical ResearchFountain ValleyCalifornia92708-
Ark Clinical ResearchLong BeachCalifornia90815-
Catalina Research Institute, LLCMontclairCalifornia91763-
Paradigm Clinical Research Centers, LLCSan DiegoCalifornia92108-
Southwest General Healthcare CenterFort MyersFlorida33907-
Panax Clinical ResearchMiami LakesFlorida33014-
Clinical Site Partners, LLC dba Flourish ResearchWinter ParkFlorida32789-
David Kavtaradze MD, IncCordeleGeorgia31015-
Excel Clinical ResearchLas VegasNevada89109-
Diabetes and Endocrinology Associates of Stark CountyCantonOhio44718-
Elligo Health Research, Inc.AustinTexas78704-
Zenos Clinical ResearchDallasTexas75230-
Synergy Groups MedicalHoustonTexas77061-
Epic Clinical ResearchLewisvilleTexas75057-
Synergy Group Medical LLCMissouri CityTexas77459-
Manassas Clinical Research CenterManassasVirginia20110-

Find similar trials in Birmingham, AL

Nationwide
Type 2 diabetes trialsEndocrinology trialsMetabolic health trialsWeight loss trials
By condition
Type 2 diabetes
By specialty
EndocrinologyMetabolic healthWeight loss
By research site
Central Research Associates, LLC dba Flourish Research· Birmingham, ALHope Clinical Research· Canoga Park, CAArk Clinical Research· Fountain Valley, CAArk Clinical Research· Long Beach, CACatalina Research Institute, LLC· Montclair, CAParadigm Clinical Research Centers, LLC· San Diego, CA

Related Studies